Vnitr Lek 2009, 55(7-8):618-621

Metabolic syndrome

M. Souček
II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.

Metabolic syndrome (MS) has become one of the topical health issues in developed countries. This arises from its increasing prevalence in the population linked to poor lifestyles (stress, overeating, lack of physical activity, smoking) and from its proven significantly negative association with the development of atherosclerosis and thus increased cardiovascular mortality and morbidity. Nevertheless, the approaches to effective MS prevention are known as are the ways of treating and preventing MS sequelae. Prerequisite, however, is an early diagnosis of MS that should become integral to common clinical practice of internal as well as general medicine practitioners.

Keywords: metabolic syndrome; obesity; diabetes mellitus; hypertension; dyslipidemia

Received: April 16, 2009; Published: July 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Souček M. Metabolic syndrome. Vnitr Lek. 2009;55(7-8):618-621.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607. Go to original source... Go to PubMed...
    2. Alberti KG, Zimmet PZ. Definition, diagnosis and classifications of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553. Go to original source... Go to PubMed...
    3. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16: 442-443. Go to original source... Go to PubMed...
    4. Executive summary of the third report of the NCEP expert panel on detection, evalution and treatment of high cholesterol in adults (Adult treatment panel III). JAMA 2001; 285: 2486-2497. Go to PubMed...
    5. Svačina Š a kol. Metabolický syndrom. 3. rozšířené a přepracované vydání. Praha: Triton 2006.
    6. Muntner P, He J, Chen J et al. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 2004; 14: 686-695. Go to original source... Go to PubMed...
    7. Cífková R, Škodová Z, Lánská V et al. Trends in blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2000/01. J Hypertens 2004; 22: 1479-1485. Go to original source... Go to PubMed...
    8. Alexander CM, Landsman PB, Teutssch SM et al. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP): NCEP - defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-1214. Go to original source... Go to PubMed...
    9. Mancia G, Parati G, Borghi C et al. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J Hypertens 2006; 24: 837-843. Go to original source... Go to PubMed...
    10. Bøg-Hansen E, Lindblad U, Gullberg B et al. Metabolic disorders associated with uncontrolled hypertension. Diabetes Obes Metab 2003; 5: 379-387. Go to original source... Go to PubMed...
    11. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716. Go to original source... Go to PubMed...
    12. Malik S, Wong ND, Franklin SS et al. The impact of the metabolic syndrome and diabetes on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250. Go to original source... Go to PubMed...
    13. Malik S, Wong ND, Franklin S et al. Cardiovascular disease in U.S. persons with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 2005; 28: 690-693. Go to original source... Go to PubMed...
    14. Zeller M, Steg PG, Ravisy J et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 2005; 165: 1192-1198. Go to original source... Go to PubMed...
    15. Petrlová B, Rosolová H, Hess Z et al. Depressive disorders and the metabolic syndrome of insulin resistance. Semin Vasc Med 2004; 4: 161-165. Go to original source... Go to PubMed...
    16. Němec P, Goldbergová-Pávková M, Gatterová J et al. Asociace promotorového polymorfismu - 1082 G/A v genu pro interleukin-10 s produkcí autoprotilátek u revmatoidní artritidy. Čes Revmatol 2008; 16: 104-109.
    17. Nemec P, Pavkova-Goldbergova M, Stouračova M et al. Polymorphism in the tumor necrosis factor-alpha gene promoter is associated with severity of rheumatoid arthritis in the Czech population. Clin Rheumatol 2008; 27: 59-65. Go to original source... Go to PubMed...
    18. Grundy SM, Hansen B, Smith SC Jr et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109: 551-556. Go to original source... Go to PubMed...
    19. Svačinová H, Nováková M, Placheta Z et al. Benefit of combined cardiac rehabilitation on exercise capacity and cardiovascular parameters in patients with type 2 diabetes. Tohoku J Exp Med 2008; 215: 103-111. Go to original source... Go to PubMed...
    20. Svačinová H. Pohybová léčba u pacientů s metabolickým syndromem. Vnitř Lék 2007; 53: 540-544. Go to PubMed...
    21. Dahlöf B, Sever PS, Poulter NR et al. for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906. Go to original source... Go to PubMed...
    22. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.